SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending due to anticipation surrounding its earnings report, with the community actively discussing revenue expectations, EPS, and guidance updates. Community members are debating whether the stock will experience a post-earnings surge or a "sell the news" pullback, a pattern observed in previous earnings cycles. The broader context includes potential tailwinds from expected rate cuts and the possibility of S&P 500 inclusion.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to a new partnership with OpenAI, with the community bullish on its potential impact on future payment infrastructure and driving the stock price higher. Investors are also anticipating upcoming earnings, hoping for positive results to further fuel the upward momentum. Discussions include potential price targets and the possibility of a short squeeze.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a bullish narrative, with many highlighting the potential impact of new ETFs and a generally positive market outlook.  Enthusiasm is high, and the community is expressing conviction with the "WAGMI" (We Are All Gonna Make It) mantra.  Discussions also mention specific Solana-based meme coins and projects gaining traction within the ecosystem.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention as community members highlight its strong community and potential within the Solana ecosystem. Some view it as a long-term hold, with potential for significant growth as Solana gains traction. The community emphasizes the "We're All Gonna Make It" (WAGMI) ethos and its potential to disrupt traditional systems.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors discuss its upcoming earnings report and potential impact on the healthcare sector. Community members are weighing in on whether the company can maintain its guidance amid industry-wide cost pressures, and some anticipate a positive reaction based on Warren Buffett's investment and potential for a strong outlook. Traders are also closely watching for news related to ACA subsidies and the DOJ case, which could act as catalysts.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors digest recent earnings and guidance, with community sentiment split between those seeing a buying opportunity and those anticipating further declines. Discussions revolve around the company's cost-cutting measures, Q4 revenue outlook, and the sustainability of its dividend yield. The broader context includes concerns about demand, labor costs, and competition in the logistics sector.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as discussions swirl around the potential launch of a Hedera ETF, with the community anticipating increased institutional investment and broader market exposure; some community members highlight Hedera's enterprise use cases and real-world adoption as key factors driving positive sentiment, while others are wary of potential short-term pullbacks or rug pulls.

Pump.fun

Pump.fun ($PUMP) is trending amid discussions about potential breakouts and community support on the Solana blockchain. There's a strong sense of optimism with many using the hashtag $WAGMI (We're All Gonna Make It), though some caution against excessive spam. The community is focused on long-term growth and shared success within the $SOL ecosystem.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is trending as the community rallies around its fully circulated supply, organic growth, and multichain functionality across $SOL, $BSC, $CRO, and $ETH. Community members highlight its deflationary nature and partnerships, expressing strong bullish sentiment and encouraging others to "caw caw" their way into the project. Discussions also point to potential staking opportunities and the coin's strong ties to multiple chains.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbean is trending amid an updated full-year EPS outlook, driven by strong demand and high guest satisfaction. Community chatter highlights the stock's volatile reactions to earnings, with some anticipating further gains while others express concerns about valuation. The cruise line sector's recovery, innovative ships, and exclusive destinations remain key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

Equity

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?

AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs. 

Eli Lilly's stock jumped over 5% on Tuesday after U.S.President Donald Trump unveiled a plan to lower U.S. drug prices, which included a “TrumpRx” direct-to-consumer website and a pricing agreement with Pfizer.&nbsp;Pfizer became the first company to accept the administration’s terms, agreeing to slash drug prices by up to 85% and secure a three-year exemption from pharmaceutical tariffs.BMO Capital Markets analyst Evan Seigerman said the Pfizer deal effectively provided a model for other drugmakers such as Eli Lilly to balance pricing cooperation with policy compliance. He said the structure gave the administration a political win while avoiding the need for harsher price controls or new tariffs, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/pfizer-to-cut-medicaid-drug-prices-in-deal-with-trump-wapo">report</a>.Cantor analyst Carter Gould said the sharp rally in pharmaceutical shares reflected investor relief that the policy measures were more symbolic than financially disruptive. He noted that Pfizer’s announcement did not change any earnings guidance, suggesting that the market viewed the move as a sign of easing regulatory uncertainty rather than a fundamental earnings risk.The S&amp;P 500 Pharmaceuticals Index rose nearly 4%, while Lilly recorded its best day in more than a month. Pfizer climbed nearly 7%, marking its strongest single-day gain in almost four years.Raymond James health policy analyst Chris Meekins said the TrumpRx program was unlikely to materially affect consumers’ costs unless insurance reforms followed. He said that if the administration’s pricing actions stopped at this stage, it would amount to a win for the pharmaceutical industry, CNN&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2025/09/30/politics/pfizer-drug-prices-trump">noted</a>.Meanwhile, Futurum Equities chief market strategist Shay Baloor&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/StockSavvyShay/status/1973057650150764638">wrote on X</a> that Trump’s agreement with Pfizer to launch TrumpRx, which allows consumers to buy discounted medications directly from manufacturers, could hurt insurers and pharmacy benefit managers.&nbsp;Baloor viewed companies such as Eli Lilly, UnitedHealth, Cigna, and Walgreens as potential losers from the shift, while naming Hims &amp; Hers Health among the likely beneficiaries.Eli Lilly stated that it was in active discussions with the administration to expand patient access, signaling its readiness to participate in broader efforts to increase affordability. The statement followed Trump’s call for drugmakers to align U.S. prices with international levels under his “Most Favored Nation” directive.Commerce Secretary Howard Lutnick said negotiations with major drugmakers were ongoing, while Trump described the plan as a step toward ending what he called global price disparities in medicine.Eli Lilly has not disclosed details of its discussions but said it remains focused on expanding access and improving affordability for patients in the U.S..On Stocktwits, retail sentiment was ‘bullish’ for Eli Lilly and ‘extremely bullish’ for Pfizer, with 24-hour message volumes surging 191% and 780%, respectively.<figure class="image"><img style="aspect-ratio:618/55;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_10_14_21_PM_png_d8474c8869.webp" alt="Screenshot 2025-09-30 at 10.14.21 PM.png" width="618" height="55"><figcaption>LLY sentiment and message volume as of 10:15 p.m. ET, Sept. 30 | source: Stocktwits</figcaption></figure>One user noted that the new TrumpRx model, which eliminates middlemen, is unlikely to impact margins for companies such as Eli Lilly, Merck, and Pfizer, describing it as a direct-to-consumer shift.&nbsp;<stembedurl>https://stocktwits.com/Jessdog77/message/630503208</stembedurl>Another user described Eli Lilly as a strong performer that continues to show unstoppable momentum.<stembedurl>https://stocktwits.com/Stonkapedia/message/630566985</stembedurl><a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> has declined 0.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nike-retail-investors-turn-more-bullish-as-q1-performance-confirms-turnaround-progress-good-report-in-difficult-market/chCooXAR39N">Nike Retail Investors Turn More Bullish As Q1 Performance Confirms Turnaround Progress: 'Good Report In Difficult Market'</a>

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma

Analysts said the plan signals a political win that could reshape how major drugmakers engage with U.S. policymakers.

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

SPDR Series Trust - SPDR Biotech ETF

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBISPDR S&P Biotech ETF